In a report released today, Justin Keywood from Stifel Nicolaus maintained a Buy rating on Knight Therapeutics (KHTRF – Research Report), with ...

Stock analysts at Leede Financial issued their FY2027 earnings per share (EPS) estimates for Cipher Pharmaceuticals in a ...

Research analysts at Leede Financial lowered their FY2025 earnings per share estimates for Cipher Pharmaceuticals in a research note issued to investors on Wednesday, March 19th. Leede Financial ...

In a report released today, Justin Keywood from Stifel Nicolaus maintained a Buy rating on Knight Therapeutics (KHTRF – Research Report), with ...

Following the company’s fourth quarter results, Leede Financial analyst Douglas Loe has upgraded Cipher Pharmaceuticals.

Cipher Pharmaceuticals Inc (CPHRF) reports a remarkable 141% increase in net revenue, driven by strategic acquisitions and robust product performance.

Cipher Pharmaceuticals (TSE:CPH) has had a rough three months with its share price down 21%. However, stock prices ...

Investing in Canadian growth stocks such as Cipher and Lumine can help you generate outsized gains in 2025 and beyond.

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology.

How much is Cipher Pharmaceuticals Inc stock worth? Invest with precise valuations. Get Report.